Mirae Asset Global Investments Co. Ltd. Purchases 7,541 Shares of Guardant Health, Inc. $GH

Mirae Asset Global Investments Co. Ltd. acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) during the third quarter, according to its most recent filing with the SEC. The firm acquired 7,541 shares of the company’s stock, valued at approximately $1,345,000.

Other institutional investors also recently bought and sold shares of the company. Financial Network Wealth Advisors LLC raised its position in Guardant Health by 17.2% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 423 shares of the company’s stock worth $75,000 after buying an additional 62 shares during the last quarter. Yousif Capital Management LLC lifted its stake in shares of Guardant Health by 6.2% in the 3rd quarter. Yousif Capital Management LLC now owns 1,587 shares of the company’s stock worth $283,000 after acquiring an additional 93 shares during the period. Allworth Financial LP boosted its holdings in shares of Guardant Health by 12.4% in the second quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock valued at $161,000 after acquiring an additional 118 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Guardant Health by 14.5% in the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after acquiring an additional 122 shares in the last quarter. Finally, Slow Capital Inc. boosted its holdings in shares of Guardant Health by 0.3% in the third quarter. Slow Capital Inc. now owns 52,683 shares of the company’s stock valued at $9,397,000 after acquiring an additional 136 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Third-quarter revenue increased 36% year over year to $361 million, above the cited analyst estimate of about $351 million. Oncology revenue rose 25%, while oncology test volumes climbed 58% to 117,000. Guardant also raised its 2026 revenue guidance. Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The reported quarterly loss was $0.29 per share, narrower than the $0.39 loss a year earlier. Guardant Health Reports Q3 Loss, Tops Revenue Estimates
• Neutral Sentiment: A separate article suggested GH could be undervalued, while noting a board appointment as a factor investors may consider in assessing the company’s valuation. Guardant Health Could Be 17% Undervalued As Board Appointment Tests Valuation
• Negative Sentiment: The main drag was a higher cash-burn forecast, which raised concerns about spending and the path to profitability despite accelerating sales. Reports said the stock declined following the earnings announcement. Guardant Health Shares Fall as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth

Insider Activity at Guardant Health

In other Guardant Health news, Director Steve E. Krognes sold 6,674 shares of Guardant Health stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the completion of the transaction, the director owned 7,906 shares in the company, valued at approximately $1,389,400.44. The trade was a 45.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Darya Chudova sold 7,738 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the completion of the transaction, the chief technology officer directly owned 70,635 shares of the company’s stock, valued at approximately $12,573,030. This trade represents a 9.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 163,060 shares of company stock valued at $27,538,217 in the last 90 days. 5.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GH. Stifel Nicolaus boosted their price target on shares of Guardant Health from $130.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Mizuho lifted their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Guggenheim lifted their price objective on Guardant Health from $190.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, October 1st. UBS Group boosted their target price on Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Finally, Piper Sandler reissued an “overweight” rating on shares of Guardant Health in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $191.00.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $150.87 on Friday. The business’s 50 day simple moving average is $169.31 and its 200-day simple moving average is $132.00. The firm has a market capitalization of $20.25 billion, a price-to-earnings ratio of -41.00 and a beta of 1.67. Guardant Health, Inc. has a 12 month low of $74.55 and a 12 month high of $191.05.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. During the same quarter in the prior year, the company earned ($0.74) EPS. The business’s revenue was up 36.1% on a year-over-year basis. On average, equities analysts anticipate that Guardant Health, Inc. will post -3.08 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring.

Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.